Orient Technologies (NSE: ORIENTTECH) Q3 FY26 results: Why short-term margin pain may be the price of securing long-cycle government and services revenue
Read More 5 minute read Healthcare Industry News Lumos Diagnostics (ASX: LDX) reaches 500-patient milestone in FebriDx CLIA study Lumos Diagnostics hits a key 500-patient milestone in its FebriDx CLIA waiver study, triggering BARDA funds. FDA application expected by October 2025. byPallavi MadhirajuJune 19, 2025